Donoghue Forlines’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,216
| Closed | -$255K | – | 207 |
|
|
2024
Q3 | $255K | Sell |
2,216
-10,955
| -83% | -$1.26M | 0.07% | 210 |
|
|
2024
Q2 | $1.81M | Buy |
13,171
+11,320
| +612% | +$1.56M | 0.52% | 35 |
|
|
2024
Q1 | $255K | Buy |
1,851
+303
| +20% | +$41.8K | 0.07% | 211 |
|
|
2023
Q4 | $204K | Buy |
+1,548
| New | +$204K | 0.06% | 213 |
|
|
2023
Q3 | – | Sell |
-3,174
| Closed | -$299K | – | 266 |
|
|
2023
Q2 | $299K | Buy |
+3,174
| New | +$299K | 0.09% | 225 |
|
|
2023
Q1 | – | Sell |
-1,727
| Closed | -$206K | – | 246 |
|
|
2022
Q4 | $206K | Sell |
1,727
-233
| -12% | -$27.8K | 0.07% | 218 |
|
|
2022
Q3 | $208K | Buy |
+1,960
| New | +$208K | 0.08% | 226 |
|
|
2021
Q1 | – | Sell |
-6,713
| Closed | -$643K | – | 272 |
|
|
2020
Q4 | $643K | Buy |
+6,713
| New | +$643K | 0.12% | 186 |
|